Through the screening of the drug library, we determined that the combined use of ATRA and tamoxifen can synergistically inhibit the proliferation of ERα-positive ovarian cancer, and explored the mechanism by which the combined drug promotes the death of ERα-positive ovarian cancer, and clarified the role of ATRA and tamoxifen. The gene discussed is ESR1; the disease is ovarian carcinoma.